BioMS brings New hope for Multiple Sclerosis Patients with a progressive form this disease
Posted Nov 17 2009 10:20pm
The potential to capture the Progressive Multiple Sclerosis Market. • Up to 75% of MS patients carry either HLA-DR2 or HLA-DR4 immune response genes. • MBP8298 demonstrated statistically significant clinical results in patients with these genes.
Statistically Significant Results in Patients with HLA-DR2 or HLA-DR4 Genes MBP8298 is entering late-stage trials in secondary progressive MS BioMS Medical Corp. is a development stage company, with its primary focus being the development and commercialization of a medical treatment for multiple sclerosis.
. Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You ============================================